| SEC Form 4 |
|------------|
|------------|

FORM 4

1. Name and Address of Reporting Person

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| OMB APPROVAL | | | | | | | | |
|--------------------------|-----|--|--|--|--|--|--|--|
| OMB Number: 3235-0287 | | | | | | | | |
| Estimated average burden | | | | | | | | |
| hours per response: | 0.5 | | | | | | | |

5. Relationship of Reporting Person(s) to Issuer

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading Symbol

| Rubric Capital Management LP | | | | The | TherapeuticsMD, Inc. [TXMD] | | | | | | | | (Chec X | k all app Direc | | 2 | - | Owner | |
|---|---|--|---|--|--|---|--|----------------------------|--------|----------------------|--|---|---|---|--|---|--|--|--|
| (Last) 155 EAS | | rst) (I Г, SUITE 1630 | Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 12/30/2022 | | | | | | | | | | Office below | , | e y remai | belov | r (specify w) | |
| (Street) NEW YORK NY 10017 | | | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) 01/03/2023 | | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting | | | | | | |
| (City) | (St | | Zip) | | | | | | | | | | | Perso | - | | | | |
| Table I - Non-Derivat 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yet) | | | on Year) | n 2A. Deemed Execution Date, | | e, | 3. 4. Securitie: Transaction Disposed O Code (Instr. 0 | | | Acquire | d (A) or | 5. Amount of Securities Beneficially Owned Following | | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | | 7. Nature of Indirect Beneficial Ownership | | | |
| | | | | | | | | Code | v | Amount | (A) or (D) Price | | | Reported Transaction(s) (Instr. 3 and 4) | | | | (Instr. 4) | |
| | Series A Preferred Stock, par value \$0.001 per share | | 12/30/20 | 022 | | | | D | | 29,000 | D | \$1,33 | 3(1) | ³⁽¹⁾ 0 | | Ι | | See footnote ⁽²⁾ | |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | Expiration I (Month/Day | | | 7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4) | | De Se (In | Price of rivative curity str. 5) | 9. Number derivative Securitie Beneficia Owned Following Reported Transacti (Instr. 4) | e s ally g | 10. Ownersh Form: Direct (D or Indire (I) (Instr. | Beneficial Ownership ct (Instr. 4) | |
| | | | | Code | v | (A) | (D) | Date Exer | cisabl | Expiration e Date | Title | Amoun or Numbe of Shares | r | | | | | | |
| | | f Reporting Person [*] /lanagement l | L <u>P</u> | | | | | | | | | | | | | | | | |
| (Last) 155 EAS | | (First) F, SUITE 1630 | (Middle) | | | | | | | | | | | | | | | | |
| (Street) NEW YO | ORK | NY | 10017 | | _ | | | | | | | | | | | | | | |
| (City) | | (State) | (Zip) | | | | | | | | | | | | | | | | |
| | nd Address of David Ef | Reporting Person [*] | | | | | | | | | | | | | | | | | |
| (Last) 155 EAS | | (First) F, SUITE 1630 | (Middle) | | | | | | | | | | | | | | | | |
| (Street) NEW YO | ORK | NY | 10017 | | | | | | | | | | | | | | | | |
| (City) | | (State) | (Zip) | | | | | | | | | | | | | | | | |

Explanation of Responses:

1. The Series A Preferred Stock was mandatorily redeemed by the Issuer pursuant to Section 6(b) of the Certificate of Designation, Preferences and Rights of Series A Preferred Stock, establishing the powers designations, preferences and privileges, and the qualifications, limitations or restrictions of the Series A Preferred Stock (the "Series A Preferred Stock COD") at a redemption price of \$1,333 per share. A copy of Series A Preferred Stock COD was filed by the Issuer as Exhibit 3.1 of the Current Report on Form 8-K filed by the Issuer with the Securities and Exchange Commission on August 1, 2022

2. This Form 4 is filed by Rubric Capital Management LP ("Rubric Capital") and Mr. David Rosen, with respect to the securities held by certain funds and/or accounts (collectively, the "Rubric Vehicles"). Rubric Capital serves as the investment advised to the Rubric Vehicles. Mr. David Rosen serves as the Managing Member of Rubric Capital Management GP, LLC, the general partner of Rubric Capital. The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Remarks:

The Reporting Persons are directors by deputization for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, by virtue of the fact that Justin Roberts, a Partner at Rubric Capital, serves on the board of directors of the Issuer

Rubric Capital Management LP, By: /s/ Michael Nachmani, 02/22/2023 its Chief Operating Officer 02/22/2023 /s/ David Rosen

Date ** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.